logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Sarepta Pharmaceuticals Jumps on Competitor’s Failure

  +Follow August 16, 2013 9:54AM
Share:
Tickers Mentioned:

Sarepta Therapeutics Inc. (SRPT) experienced a bit of schadenfreude on Aug. 16 as a direct competitor stumbled badly at the finish line.

Competitor GlaxoSmithKline plc (GSK) had been neck-and-neck with Serepta in the race to develop a breakthrough muscle disorder drug to treat Duchenne Muscular Dystrophy. Both drugs were far ahead of the pack in the development process.

That is, until Baird analyst Brian Skorney reported that Glaxo’s drug, drisapersen, has encountered major stumbling blocks on several fronts that could significantly hamper development. Skorney cited clinical, regulatory, and commercials issues with the drug. Most importantly, the drug did not seem to effectively treat symptoms of the disease at the targeted dose.

Serepta’s drug, eteplirsen, so far has seemed to be effective at treating symptoms of Duchenne. Clinical trials have taken place in the UK. On Aug. 7 the company released promising clinical trial information, which will form the basis of their application for US FDA approval in early 2014.

Duchenne is a severely debilitating form of muscular dystrophy. The recessive muscular degenerative disorder affects approximately 1 in 3,600 boys, and life expectancy for sufferers is usually around 25. A drug from either company would be the first on the American market designed to treat the disorder.

The London-based GlaxoSmithKline , which is the fourth largest pharmaceutical company in the world, shrugged off the setback. Their stock is up .33 percent to hit $51.70 a share.

Serepta is up 6.77 percent to hit $34.21 a share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

				
				
  +Follow August 16, 2013 9:54AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.